Ask what kind of product is proposed
Peptide describes a substance’s structure, the way its parts fit together. It is not a type of approval. Each specific product has its own status under federal rules, checked November 3, 2026. A product’s status depends on what it is and how it is supplied.
Ask the service to name the proposed product without a package name or a broad phrase such as wellness care. Write down the substance intended to produce the effect, called the active ingredient. Add the form in which it would be supplied. Keep those details together.
Ask which of these fits the offer: a ready-made approved medicine; a preparation mixed to order, called a compound; or a chemical for laboratory work? Do not fill in that answer from the website’s design. If a reply moves between those descriptions, ask which description applies to the actual product under discussion.
An approval belongs to a specific product
The November 3, 2026 FDA record check includes semaglutide products under Ozempic and Wegovy. Tirzepatide products under Mounjaro and Zepbound also have approvals, with uses set out on their respective labels.
A label is the official product information. Ask which product information supports the proposed use. Have the person explain how that information relates to your own concern. A list of familiar medicine names does not tell you which product a service intends to prescribe.
A listing may carry an NDC, short for National Drug Code. That code is not proof of product approval. FDA makes that distinction explicitly, and it was checked November 3, 2026.
A page showing a product name and an NDC number may only be a directory listing. If that is the proof offered, ask the service to open the FDA approval record for that exact product and show its approved uses. Keep the product name visible while reading that record. Similar names, alternate forms and a broad family of treatments are easy to confuse when comparing tabs on a phone.
Compounding is a different route
Compounding involves preparing a medicine rather than supplying an approved finished product. FDA does not review a compounded preparation for quality, effectiveness or safety before marketing; this position was checked November 3, 2026.
That makes the reason for proposing a compound an important question. Ask what need the preparation is intended to meet and why an approved product would not meet it. Also ask who prepares it. A service arranging the consultation may be different from the pharmacy making the medicine.
Keep the explanation about the product separate from the explanation about the pharmacy. You need to know both what is being proposed and who is responsible for supplying it. The compounding chapter sets out the terms that help you follow that discussion without turning it into a chemistry lesson.
Research wording is not a care plan
FDA has sent sellers warning letters describing suspected legal violations. In those letters, FDA has said that promises about effects on people show a product is being offered as a drug. Calling the product research material does not cancel those promises. That recorded position was checked November 3, 2026.
Ask whether a licensed professional will assess you and, if treatment is appropriate, prescribe a named medicine. Or is the item being offered only as a chemical for laboratory work? Ask for an answer about medical care for you, rather than accepting a research label as permission for treatment. Do not treat the latter description as an answer about care. Return to the named person, named product and written reason for the proposal.
The useful outcome of this chapter is a short, exact description you can repeat to another health professional. If that description is still unclear, the comparison is not ready for a price decision. Keep the offer and request clarification in writing.